Advertisement

Etoposide: A pharmacokinetic profile including an assessment of bioavailability

  • D. Cunningham
  • Lesley McTaggart
  • M. Soukop
  • J. Cummings
  • G. J. Forrest
  • J. F. B. Stuart
Articles
  • 30 Downloads

Abstract

The pharmacokinetics of intravenous etoposide (50–150 mg m−2) have been studied in 17 patients. Bioavailability studies on either the capsule or intravenous (i.v.) formulation were performed in 13 patients, 7 of whom received both oral formulations given in the dose range 50–250 mg m−2. After i.v. administration the mean±SD half-lives weret 1/2α 0.62±1.01 h andt 1/2β 6.04±2.5 h. The bioavailability of etoposide was extremely variable: for the capsule it was 38±14% (range 10–55) and for the i.v. formulation it was 53±25% (range 31–88). The i.v. formulation was not significantly better than the capsule. The results confirm the low and variable bioavailability of oral etoposide.

Key words

Etoposide Pharmacokinetics Bioavailability 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Dwyer P J, Leyland-Jones B, Alonso M Tet al: Drug therapy, etoposide (VP-16-213): current status of an active anti-cancer drug.New Engl J Med 312, 692 (1985).PubMedGoogle Scholar
  2. 2.
    D’Incalci M, Farina P, Sessa Cet al: Pharmacokinetics of VP16-213 given by different administration methods.Cancer Chemother Pharmac 7, 141 (1982).Google Scholar
  3. 3.
    Harvey V J, Slevin M L, Joel S Pet al: The pharmacokinetics of oral etoposide (VP16-213).Proc Am Soc Clin Oncol 3, 24 (1984).Google Scholar
  4. 4.
    Farina P, Marzillo G, D’Incalci M: High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasma.J Chromatogr 222, 141 (1981).PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart D J, Nundy D, Maroun J Aet al: Biovailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.Cancer Treatment Rep 69, 269 (1985).Google Scholar

Copyright information

© Humana Press Inc. 1986

Authors and Affiliations

  • D. Cunningham
    • 1
  • Lesley McTaggart
    • 2
  • M. Soukop
    • 1
  • J. Cummings
    • 3
  • G. J. Forrest
    • 1
  • J. F. B. Stuart
    • 2
  1. 1.Department of Medical OncologyRoyal InfirmaryGlasgowU.K.
  2. 2.Department of Pharmacy and TherapeuticsStrathclyde UniversityGlasgowU.K.
  3. 3.University Department of Medical OncologyGlasgowU.K.

Personalised recommendations